Galectin Therapeutics (GALT) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program
May 11, 2015 8:01 AM EDTNORCROSS, Ga., May 11, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three months ended March 31, 2015. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission.
Management commentary
"We made excellent progress during the quarter and recent weeks toward the imminent commencement of our Phase 2 program with GR-MD-02 for the treatment of nonalcoholic... More
